Prospects of levetiracetam as a neuroprotective drug against status epilepticus, traumatic brain injury, and stroke

Frontiers in Neurology

Volumn 4 NOV, Issue , 2013, Pages

  Shetty, Ashok K ^a,b,c  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Acute seizures; Chronic epilepsy; Epileptogenesis; Neurodegeneration; Post traumatic epilepsy; Post traumatic seizures; Stroke; Traumatic brain injury

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CELL PROTEIN; DIAZEPAM; ETIRACETAM; NEUROPROTECTIVE AGENT; PHENYTOIN; PROTEIN SV2A; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE DISEASE; ADD ON THERAPY; ANTICONVULSANT ACTIVITY; ARTICLE; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DISEASE CONTROL; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; FOCAL EPILEPSY; HUMAN; MEMORY DISORDER; MENTAL PERFORMANCE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROMODULATION; NONHUMAN; PATIENT MONITORING; SEIZURE; SINGLE DRUG DOSE; TONIC CLONIC SEIZURE; TRAUMATIC BRAIN INJURY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84889670378     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2013.00172     Document Type: Article

References (44)

1. Surges R, Volynski KE, Walker MC. Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Ther Adv Neurol Disord (2008) 1:13-24. doi: 10.1177/1756285608094212
2. Zou H, Brayer SW, Hurwitz M, Niyonkuru C, Fowler LE, Wagner AK. Neuroprotective, neuroplastic, and neurobehavioral effects of daily treatment with levetiracetam in experimental traumatic brain injury. Neurorehabil Neural Repair (2013) 27(9):878-88. doi:10.1177/1545968313491007
3. De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev (2007) 13:43-56. doi:10.1111/j.1527-3458.2007.00005.x
4. De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev (2007) 13:57-78. doi:10.1111/j.1527-3458.2007.00005.x
5. Crepeau AZ, Treiman DM. Levetiracetam: a comprehensive review. Expert Rev Neurother (2010) 10:159-71. doi:10.1586/ern.10.3
6. Wang H, Gao J, Lassiter TF, McDonagh DL, Sheng H, Warner DS, et al. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care (2006) 5(1):71-8. doi:10.1385/NCC:5:1:71
7. Gibbs JE, Cock HR. Administration of levetiracetam after prolonged status epilepticus does not protect from mitochondrial dysfunction in a rodent model. Epilepsy Res (2007) 73:208-12. doi:10.1016/j.eplepsyres.2006.09.005
8. Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care (2010) 12:165-72. doi:10.1007/s12028-009-9304-y
9. Steinbaugh LA, Lindsell CJ, Shutter LA, Szaflarski JP. Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention. Epilepsy Behav (2012) 23:280-4. doi:10.1016/j.yebeh.2011.12.005
10. Ueda Y, Doi T, Tokumaru J, Yokoyama H, Nakajima A, Mitsuyama Y, et al. Collapse of extracellular glutamate regulation during epileptogenesis: down-regulation and functional failure of glutamate transporter function in rats with chronic seizures induced by kainic acid. J Neurochem (2001) 76(3):892-900. doi:10.1046/j.1471-4159.2001.00087.x
11. Vespa P, Prins M, Ronne-Engstrom E, Caron M, Shalmon E, Hovda DA, et al. Increase in extracellular glutamate caused by reduced cerebral perfusion pressure and seizures after human traumatic brain injury: a microdialysis study. J Neurosurg (1998) 89:971-82. doi:10.3171/jns.1998.89.6.0971
12. Takeuchi H, Jin S, Suzuki H, Doi Y, Liang J, Kawanokuchi J, et al. Blockade of microglial glutamate release protects against ischemic brain injury. Exp Neurol (2008) 214:144-6. doi:10.1016/j.expneurol.2008.08.001
13. Zheng Y, Moussally J, Cash SS, Karnam HB, Cole AJ. Intravenous levetiracetam in the rat pilocarpine-induced status epilepticus model: behavioral, physiological and histological studies. Neuropharmacology (2010) 58:793-8. doi:10.1016/j.neuropharm.2009.12.007
14. Yan HD, Ishihara K, Seki T, Hanaya R, Kurisu K, Arita K, et al. Inhibitory effects of levetiracetam on the high-voltage-activated L-type Ca2+ channels in hippocampal CA3 neurons of spontaneously epileptic rat (SER). Brain Res Bull (2013) 2013(90):142-8. doi:10.1016/j.brainresbull.2012.10.006
15. Husum H, Bolwig TG, Sánchez C, Mathé AA, Hansen SL. Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties. Epilepsy Behav (2004) 5(2):204-15. doi:10.1016/j.yebeh.2003.12.004
16. Talos DM, Chang M, Kosaras B, Fitzgerald E, Murphy A, Folkerth RD, et al. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. Pediatr Res (2012) 73:24-30. doi:10.1038/pr.2012.151
17. Lee DS, Ryu HJ, Kim JE, Choi HC, Kim YI, Song HK, et al. The effect of levetiracetam on status epilepticus-induced neuronal death in the rat hippocampus. Seizure (2013) 22:368-77. doi:10.1016/j.seizure.2013.02.005
18. Ueda Y, Doi T, Takaki M, Nagatomo K, Nakajima A, Willmore LJ. Levetiracetam enhances endogenous antioxidant in the hippocampus of rats: in vivo evaluation by brain microdialysis combined with ESR spectroscopy. Brain Res (2009) 1266:1-7. doi:10.1016/j.brainres.2009.02.040
19. Oliveira AA, Almeida JP, Freitas RM, Nascimento VS, Aguiar LM, Júnior HV, et al. Effects of levetiracetam in lipid peroxidation level, nitrite-nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures. Cell Mol Neurobiol (2007) 27:395-406. doi:10.1007/s10571-006-9132-y
20. Margineanu DG, Matagne A, Kaminski RM, Klitgaard H. Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats. Brain Res Bull (2008) 77:282-5. doi:10.1016/j.brainresbull.2008.07.006
21. Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther (1998) 284:474-9.
22. Ishimaru Y, Chiba S, Serikawa T, Sasa M, Inaba H, Tamura Y, et al. Effects of levetiracetam on hippocampal kindling in Noda epileptic rats. Brain Res (2010) 1309:104-9. doi:10.1016/j.brainres.2009.10.056
23. Christensen KV, Leffers H, Watson WP, Sánchez C, Kallunki P, Egebjerg J. Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats. BMC Neurosci (2010) 11:9. doi:10.1186/1471-2202-11-9
24. Sugaya Y, Maru E, Kudo K, Shibasaki T, Kato N. Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus. Brain Res (2010) 1352:187-99. doi:10.1016/j.brainres.2010.06.061
25. Matveeva EA, Vanaman TC, Whiteheart SW, Slevin JT. Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes. Epilepsia (2008) 49:1749-58. doi:10.1111/j.1528-1167.2008.01687.x
26. Sugaya Y, Jinde S, Kato N, Maru E. Levetiracetam inhibits kindling-induced synaptic potentiation in the dentate gyrus of freely moving rats. Neurosci Res (2010) 66:228-31. doi:10.1016/j.neures.2009.10.014
27. Jung KH, Chu K, Kim M, Jeong SW, Song YM, Lee ST, et al. Continuous cytosine-b-D-arabinofuranoside infusion reduces ectopic granule cells in adult rat hippocampus with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Eur J Neurosci (2004) 19:3219-26. doi:10.1111/j.0953-816X.2004.03412.x
28. Scharfman HE, McCloskey DP. Postnatal neurogenesis as a therapeutic target in temporal lobe epilepsy. Epilepsy Res (2009) 85:150-61. doi:10.1016/j.eplepsyres.2009.03.006
29. Kim JE, Choi HC, Song HK, Jo SM, Kim DS, Choi SY, et al. Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats. Neurosci Lett (2010) 471:94-9. doi:10.1016/j.neulet.2010.01.018
30. Yan HD, Ji-Qun C, Ishihara K, Nagayama T, Serikawa T, Sasa M. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia (2005) 46:1170-7. doi:10.1111/j.1528-1167.2005.35204.x
31. Brandt C, Glien M, Gastens AM, Fedrowitz M, Bethmann K, Volk HA, et al. Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. Neuropharmacology (2007) 53:207-21. doi:10.1016/j.neuropharm.2007.05.001
32. Zhou JL, Zhao Q, Holmes GL. Effect of levetiracetam on visual-spatial memory following status epilepticus. Epilepsy Res (2007) 73:65-74. doi:10.1016/j.eplepsyres.2006.08.007
33. Gibbs JE, Walker MC, Cock HR. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia (2006) 47:469-78. doi:10.1111/j.1528-1167.2006.00454.x
34. Torbic H, Forni AA, Anger KE, Degrado JR, Greenwood BC. Use of antiepileptics for seizure prophylaxis after traumatic brain injury. Am J Health Syst Pharm (2013) 70:759-66. doi:10.2146/ajhp120203
35. Jones KE, Puccio AM, Harshman KJ, Falcione B, Benedict N, Jankowitz BT, et al. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg Focus (2008) 25:E3. doi:10.3171/FOC.2008.25.10.E3
36. Klein P, Herr D, Pearl PL, Natale J, Levine Z, Nogay C, et al. Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy. Arch Neurol (2012) 69:1290-5. doi:10.1001/archneurol.2012.445
37. Inaba K, Menaker J, Branco BC, Gooch J, Okoye OT, Herrold J, et al. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. J Trauma Acute Care Surg (2013) 74:766-71. doi:10.1097/TA.0b013e3182826e84
38. Kruer RM, Harris LH, Goodwin H, Kornbluth J, Thomas KP, Slater LA, et al. Changing trends in the use of seizure prophylaxis after traumatic brain injury: a shift from phenytoin to levetiracetam. J Crit Care (2013) 28(5):e9-13. doi:10.1016/j.jcrc.2012.11.020
39. Pearl PL, McCarter R, McGavin CL, Yu Y, Sandoval F, Trzcinski S, et al. Results of phase II levetiracetam trial following acute head injury in children at risk for posttraumatic epilepsy. Epilepsia (2013) 54(9):e135-37. doi:10.1111/epi.12326
40. Gilad R. Management of seizures following a stroke: what are the options? Drugs Aging (2012) 29(7):533-8. doi:10.2165/11631540-000000000-00000
41. Consoli D, Bosco D, Postorino P, Galati F, Plastino M, Perticoni GF, et al. Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). Cerebrovasc Dis (2012) 34:282-9. doi:10.1159/000342669
42. Belcastro V, Costa C, Galletti F, Autuori A, Pierguidi L, Pisani F, et al. Levetiracetam in newly diagnosed late-onset post-stroke seizures: a prospective observational study. Epilepsy Res (2008) 82:223-6. doi:10.1016/j.eplepsyres.2008.08.008
43. Kutlu G, Gomceli YB, Unal Y, Inan LE. Levetiracetam monotherapy for late poststroke seizures in the elderly. Epilepsy Behav (2008) 13:542-4. doi:10.1016/j.yebeh.2008.04.025
44. Jungehulsing GJ, Israel H, Safar N, Taskin B, Nolte CH, Brunecker P, et al. Levetiracetam in patients with central neuropathic post-stroke pain-a randomized, double-blind, placebo-controlled trial. Eur J Neurol (2013) 20:331-7. doi:10.1111/j.1468-1331.2012.03857.x